Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 3Thoracic 2Gynecologic 2Genitourinary 2Gastrointestinal 1CNS 1

Conditions

Ovarian Neoplasms 2

Interventions

Paclitaxel 233Carboplatin 217Bevacizumab 139Cisplatin 136pembrolizumab 89Gemcitabine 69olaparib 54Docetaxel 47Topotecan 44Radiotherapy 43liposomal doxorubicin 41Taxes 41niraparib 38Cyclophosphamide 36Doxorubicin 30Drug Therapy 29Letrozole 28Nivolumab 27Magnetic Resonance Spectroscopy 25Immunoglobulin G 25Disulfides 24Oxaliplatin 23Albumin-Bound Paclitaxel 23durvalumab 22apatinib 21Etoposide 21Brachytherapy 21lenvatinib 20camrelizumab 20Specimen Handling 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × paclitaxel poliglumex × Gynecologic × Clear all
NCT00045682 2017-07-13

CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

GOG Foundation

Phase 2 Completed
78 enrolled
Gynecologic

Ovarian Neoplasms

NCT00069901 2008-09-22

Phase II CT-2103/Carboplatin in Ovarian Cancer

CTI BioPharma

Phase 2 Completed
82 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡